Publication

Article

CURE

Summer 2007
Volume6
Issue 4

www.re-mission.net

Author(s):

Elizabeth Whittington

Gamers take virtual shot at cancer.

Teens and young adults fighting cancer can now really battle the disease with Re-Mission, a video game that pits a robot called Roxxi against cancer cells and bacterial infections, while dealing with side effects at a microscopic level within the bodies of fictional patients. HopeLab, a nonprofit focused on children with chronic illnesses, developed the video game with game developers, animators, psychologists, and scientists. Re-Mission is available free at www.re-mission.net. The website also offers an online community for teens and young adults with cancer.

Articles in this issue
How to Find Help
Job Transitions, Insurance Change
Medicare Coverage for Colon Cancer Screenings
Noting Group Differences
The Journey of Cancer Survivorship
Beauty Shopping
Pregnancy After Cancer
Fast Facts: Richard Roundtree
Portal Authority
Precious Tumor
Surviving "Survivor" Stereotypes
The Secret of Caregivers
Surgeons and Robots
A Hole In The World
Making the Most of a Portal
Related Videos
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Related Content
Image of sunset.
March 7th 2025

The Dawn of a New Era in Cancer Treatment

Mike Hennessy Jr.
New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of woman. Image Credit: Rachael Boer.
March 5th 2025

Organ-Sparing Treatments Bring New Life After Cancer

Sonya Collins
Avoiding surgery for rectal cancer, Sarah Rack of Memphis traveled to Houston for treatment every three weeks for 18 months.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Transplant and chemo replaced with CI-based therapy and ISRT maintains survival in younger patients with cHL; © LukaszDesign - stock.adobe.com
March 4th 2025

Checkpoint Inhibitor Therapy and ISRT Maintains Outcomes in Younger Patients With cHL

Ryan Scott
Replacing transplant and chemo with CI-based therapy and ISRT maintains survival, reduces side effects in younger patients with classic Hodgkin lymphoma.
Cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma; © Nattapat - stock.adobe.com
February 28th 2025

Cema-Cel Has Durable Responses in in Relapsed/Refractory Large B-Cell Lymphoma

Ryan Scott
Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.